Sequential therapy for lymphoma not fully responding to initial treatment
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new sequence of chemotherapy drugs for people with intermediate-to-high risk diffuse large B-cell lymphoma who did not achieve complete remission after their first two cycles of standard treatment. The goal is to see if this approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with diffuse large B-cell lymphoma (a type of blood cancer)
- Your IPI score (a risk score) is greater than 2, meaning intermediate-to-high risk
- You have not achieved complete remission after 2 cycles of standard RCHOP or RCDOP chemotherapy
- You have at least one tumor that can be measured (larger than 1.5 cm in a lymph node or 1.0 cm elsewhere)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a specific treatment plan to see how well it works for adults with newly diagnosed non-Hodgkin lymphoma that has a high amount of disease. It may help by aiming to control lymphoma more effectively, especially when it is widespread.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This trial tests a new combination of drugs (R-CMOP) for people who have just been diagnosed with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) and have not yet received any treatment for it. The goal is to see if this treatment works well and is safe.
This trial tests a lower-dose combination of chemotherapy drugs (R-mini-MCOP) for people aged 80 or older who have just been diagnosed with a common type of lymphoma called DLBCL. The goal is to see if this gentler approach is effective and easier to tolerate.
This trial tests a combination of four drugs (homoharringtonine, a BCL-2 inhibitor, rituximab, and prednisone) for people with diffuse large B-cell lymphoma that has come back or not responded to earlier treatment. It aims to see if this new mix can help when standard therapies have stopped working.
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.